| Publications | PubMed=3567358; DOI=10.1182/blood.V69.5.1307.1307
Tweeddale M.E., Lim B., Jamal N., Robinson J., Zalcberg J.R., Lockwood G., Minden M.D., Messner H.A.
The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor.
Blood 69:1307-1314(1987) PubMed=7849311; DOI=10.1182/blood.V85.4.893.bloodjournal854893
Stranks G., Height S.E., Mitchell P., Jadayel D.M., Yuille M.A.R., De Lord C., Clutterbuck R.D., Treleaven J.G., Powles R.L., Nacheva E., Oscier D.G., Karpas A., Lenoir G.M., Smith S.D., Millar J.L., Catovsky D., Dyer M.J.S.
Deletions and rearrangement of CDKN2 in lymphoid malignancy.
Blood 85:893-901(1995) PubMed=8574164; DOI=10.3109/10428199509059672
Chang H., Blondal J.A., Benchimol S., Minden M.D., Messner H.A.
p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines.
Leuk. Lymphoma 19:165-171(1995) PubMed=11807979; DOI=10.1002/gcc.10025
Mehra S., Messner H.A., Minden M.D., Chaganti R.S.K.
Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines.
Genes Chromosomes Cancer 33:225-234(2002) PubMed=15126345; DOI=10.1158/0008-5472.CAN-03-3773
Ota A., Tagawa H., Karnan S., Tsuzuki S., Karpas A., Kira S., Yoshida Y., Seto M.
Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma.
Cancer Res. 64:3087-3095(2004) PubMed=16960149; DOI=10.1182/blood-2006-06-026500
Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R., Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M., Rosenwald A., Sugimoto K.-j., Wheat L.M., Karran E.L., Garcia J.F., Sanchez-Verde L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S., Martinez-Climent J.A.
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas.
Blood 109:271-280(2007) PubMed=19278952; DOI=10.1182/blood-2009-01-202028
Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C., Robetorye R.S., Aguiar R.C.T.
Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.
Blood 113:6681-6690(2009) PubMed=19358282; DOI=10.1002/ijc.24351
Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M., Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.
Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
Int. J. Cancer 125:212-221(2009) PubMed=20628145; DOI=10.1182/blood-2010-05-282780
Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T., O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T.R., Kutok J.L., Shipp M.A.
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Blood 116:3268-3277(2010) PubMed=23292937; DOI=10.1073/pnas.1205299110
Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L., Mieczkowski P.A., Dunphy C., Choi W., Au W.Y., Srivastava G., Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P., Flowers C.R., Naresh K., Evens A.M., Gordon L.I., Czader M.B., Gill J.I., Hsi E.D., Liu Q.-Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J., Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S., Dunson D.B., Dave S.S.
Genetic heterogeneity of diffuse large B-cell lymphoma.
Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013) PubMed=26727417; DOI=10.3109/10428194.2015.1108414
Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.
Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.
Leuk. Lymphoma 57:1015-1020(2016) PubMed=26787899; DOI=10.1073/pnas.1524677113
Dekker J.D., Park D., Shaffer A.L. III, Kohlhammer H., Deng W., Lee B.-K., Ippolito G.C., Georgiou G., Iyer V.R., Staudt L.M., Tucker H.O.
Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.
Proc. Natl. Acad. Sci. U.S.A. 113:E577-E586(2016) |
|---|